Sreenivasa Rao Chandana

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Tanios Bekaii‐Saab · 5 shared papers, 2023–2025 · strength 1.10
   • Paper Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. DOI 10.1016/j.ejca.2023.113471↗
   • Paper Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J C… DOI 10.1016/j.ejca.2024.113941↗
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
2. Laura M. Woods · 2 shared papers, 2024 · strength 0.56
   • Paper Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. DOI 10.1016/j.ejca.2023.113471↗
   • Paper Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J C… DOI 10.1016/j.ejca.2024.113941↗
3. Zev A. Wainberg · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
4. Eileen Mary O'Reilly · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
5. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
6. Christelle de la Fouchardière · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
7. Andrew Scott Paulson · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
8. Roberto Pazo-Cid · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
9. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
   • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
   • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
   • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
10. Davide Melisi · 3 shared papers, 2023–2025 · strength 0.54
    • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
11. Richard A Hubner · 3 shared papers, 2023–2025 · strength 0.54
    • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
12. Shubham Pant · 3 shared papers, 2023–2025 · strength 0.54
    • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
13. Eric Van Cutsem · 3 shared papers, 2023–2025 · strength 0.54
    • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
14. Teresa Mercade Macarulla · 3 shared papers, 2023–2025 · strength 0.54
    • Paper Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-n… DOI 10.1016/j.esmoop.2025.105534↗
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
15. Gerald Paul Wright · 2 shared papers, 2023–2024 · strength 0.48
    • Paper Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. DOI 10.1080/08941939.2022.2129884↗
    • Paper Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resec… DOI 10.1177/00031348241250043↗
16. Hordur Mar Kolbeinsson · 2 shared papers, 2023–2024 · strength 0.48
    • Paper Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. DOI 10.1080/08941939.2022.2129884↗
    • Paper Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resec… DOI 10.1177/00031348241250043↗
17. Mathew H. Chung · 2 shared papers, 2023–2024 · strength 0.48
    • Paper Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. DOI 10.1080/08941939.2022.2129884↗
    • Paper Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resec… DOI 10.1177/00031348241250043↗
18. Daruka Mahadevan · 3 shared papers, 2019–2022 · strength 0.43
    • Paper Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1557145↗
    • Paper Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. DOI 10.1080/14656566.2022.2149322↗
    • Paper Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1632289↗
19. Hani M. Babiker · 3 shared papers, 2019–2022 · strength 0.43
    • Paper Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1557145↗
    • Paper Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. DOI 10.1080/14656566.2022.2149322↗
    • Paper Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1632289↗
20. Andrew Peter Dean · 2 shared papers, 2023–2025 · strength 0.34
    • Paper A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancrea… DOI 10.1080/14796694.2025.2458458↗
    • Paper NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
21. Alejandro Recio‐Boiles · 2 shared papers, 2019–2022 · strength 0.27
    • Paper Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. DOI 10.1080/14656566.2022.2149322↗
    • Paper Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1632289↗
22. M. Mura Assifi · 1 shared paper, 2024 · strength 0.22
    • Paper Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resec… DOI 10.1177/00031348241250043↗
23. Jesse K. Kelley · 1 shared paper, 2024 · strength 0.22
    • Paper Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resec… DOI 10.1177/00031348241250043↗
24. Harshad Kulkarni · 1 shared paper, 2024 · strength 0.21
    • Paper First-in-Human Total-Body PET/CT Imaging Using 89Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma. DOI 10.2967/jnumed.124.268074↗
25. Ryohei Kobayashi · 1 shared paper, 2024 · strength 0.21
    • Paper First-in-Human Total-Body PET/CT Imaging Using 89Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma. DOI 10.2967/jnumed.124.268074↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.